Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1986 1
1991 1
1994 2
1997 2
1998 3
1999 7
2000 5
2001 3
2002 3
2003 4
2005 9
2006 5
2007 4
2008 6
2009 5
2010 10
2011 27
2012 16
2013 14
2014 7
2015 19
2016 15
2017 14
2018 12
2019 19
2020 18
2021 19
2022 18
2023 22
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for dosing huh
Search for Dosung Huh instead (3 results)
A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice.
Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, Thorneloe KS, McAlexander MA, Ingber DE. Huh D, et al. Sci Transl Med. 2012 Nov 7;4(159):159ra147. doi: 10.1126/scitranslmed.3004249. Sci Transl Med. 2012. PMID: 23136042 Free PMC article.
This device was used to reproduce drug toxicity-induced pulmonary edema observed in human cancer patients treated with interleukin-2 (IL-2) at similar doses and over the same time frame. Studies using this on-chip disease model revealed that mechanical forces associated wi …
This device was used to reproduce drug toxicity-induced pulmonary edema observed in human cancer patients treated with interleukin-2 (IL-2) …
Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, Sung IK, Kim JI, Kim JH, Lee JS, Kwon JG, Park JH, Huh KC, Park KS, Park MI, Kim N, Lee OY, Jee SR, Lee SK, Youn SJ, Kim SK, Lee ST, Hong SJ, Choi SC, Kim TN, Youn YH, Park HJ, Kang MJ, Park CH, Kim BT, Youn S, Song GS, Rhee PL. Lee KJ, et al. Aliment Pharmacol Ther. 2019 Apr;49(7):864-872. doi: 10.1111/apt.15185. Epub 2019 Mar 6. Aliment Pharmacol Ther. 2019. PMID: 30843245 Free PMC article. Clinical Trial.
RESULTS: The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively. Both doses of tegoprazan were non-inferior to esomeprazole 40 mg. The incidence of adverse even …
RESULTS: The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg …
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group. Joura EA, et al. BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401. BMJ. 2012. PMID: 22454089 Free PMC article. Clinical Trial.
PARTICIPANTS: Among 17,622 women aged 15-26 years who underwent 1:1 randomisation to vaccine or placebo, 2054 received cervical surgery or were diagnosed with genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia. INTERVENTION: Three doses o …
PARTICIPANTS: Among 17,622 women aged 15-26 years who underwent 1:1 randomisation to vaccine or placebo, 2054 received cervical surgery or w …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) epsilon4 allele and the other involving 1331 noncarriers. Bapineuzumab o …
METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's …
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19.
Hong JY, Ko JH, Yang J, Ha S, Nham E, Huh K, Cho SY, Kang CI, Chung DR, Baek JY, Sohn YM, Park HJ, Lee B, Huh HJ, Kang ES, Suh GY, Chung CR, Peck KR. Hong JY, et al. Yonsei Med J. 2022 May;63(5):430-439. doi: 10.3349/ymj.2022.63.5.430. Yonsei Med J. 2022. PMID: 35512745 Free PMC article.
MATERIALS AND METHODS: A retrospective cohort study was conducted to evaluate the effect of severity-adjusted dosing of dexamethasone in combination with tocilizumab for severe COVID-19 from August 2020 to August 2021. ...
MATERIALS AND METHODS: A retrospective cohort study was conducted to evaluate the effect of severity-adjusted dosing of dexamethasone …
First-line medication dosing in pediatric refractory status epilepticus.
Vasquez A, Gaínza-Lein M, Abend NS, Amengual-Gual M, Anderson A, Arya R, Brenton JN, Carpenter JL, Chapman K, Clark J, Farias-Moeller R, Gaillard WD, Glauser T, Goldstein JL, Goodkin HP, Guerriero RM, Kapur K, Lai YC, McDonough TL, Mikati MA, Morgan LA, Novotny EJ, Ostendorf AP, Payne ET, Peariso K, Piantino J, Riviello JJ, Sannagowdara K, Tasker RC, Tchapyjnikov D, Topjian A, Wainwright MS, Wilfong A, Williams K, Loddenkemper T; Pediatric Status Epilepticus Research Group (pSERG). Vasquez A, et al. Neurology. 2020 Nov 10;95(19):e2683-e2696. doi: 10.1212/WNL.0000000000010828. Epub 2020 Sep 10. Neurology. 2020. PMID: 32913024 Free PMC article.
We used logistic regression modeling to evaluate predictors of low BZD dosing and multivariate Cox regression analysis to assess the impact of low BZD dosing on time to seizure cessation. ...CONCLUSION: BZD doses were lower than recommended in both out-of-hos …
We used logistic regression modeling to evaluate predictors of low BZD dosing and multivariate Cox regression analysis to assess the …
Human papillomavirus vaccination: Ongoing challenges and future directions.
Dilley S, Miller KM, Huh WK. Dilley S, et al. Gynecol Oncol. 2020 Feb;156(2):498-502. doi: 10.1016/j.ygyno.2019.10.018. Epub 2019 Dec 14. Gynecol Oncol. 2020. PMID: 31848025 Free PMC article. Review.
Since 2006, administration guidelines have undergone multiple updates regarding age, dosing schedule, and gender. Despite these changes, the basic tenet remains the same: prioritize immunization before initiation of sexual activity and subsequent exposure to HPV. ...
Since 2006, administration guidelines have undergone multiple updates regarding age, dosing schedule, and gender. Despite these chang …
Cuproptosis-Inducible Chemotherapeutic/Cascade Catalytic Reactor System for Combating with Breast Cancer.
Lee SY, Seo JH, Kim S, Hwang C, Jeong DI, Park J, Yang M, Huh JW, Cho HJ. Lee SY, et al. Small. 2023 Aug;19(35):e2301402. doi: 10.1002/smll.202301402. Epub 2023 May 10. Small. 2023. PMID: 37162448
Low biodegradation rate of designed HD/BER/GOx/Cu hydrogel can reduce dosing frequency in local cancer therapy and avoid invasiveness-related inconveniences. ...
Low biodegradation rate of designed HD/BER/GOx/Cu hydrogel can reduce dosing frequency in local cancer therapy and avoid invasiveness …
Functional nanoplatforms for enhancement of chemotherapeutic index.
Yang J, Lee E, Ku M, Huh YM, Cheong JH. Yang J, et al. Anticancer Agents Med Chem. 2013 Feb;13(2):212-21. doi: 10.2174/1871520611313020005. Anticancer Agents Med Chem. 2013. PMID: 22934694 Review.
In particular, nanoparticles designed and fabricated by sophisticated processes can (as drug carriers) deliver precise doses of multiple anti-cancer agents to target cancer cells, improving therapeutic efficacy and minimizing side effects. ...
In particular, nanoparticles designed and fabricated by sophisticated processes can (as drug carriers) deliver precise doses of multi …
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group. Sandborn WJ, et al. N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248. N Engl J Med. 2016. PMID: 27144850 Free article. Clinical Trial.
RESULTS: The primary outcome occurred in 16% of the patients who received 1 mg of ozanimod and in 14% of those who received 0.5 mg of ozanimod, as compared with 6% of those who received placebo (P=0.048 and P=0.14, respectively, for the comparison of the two doses of ozani …
RESULTS: The primary outcome occurred in 16% of the patients who received 1 mg of ozanimod and in 14% of those who received 0.5 mg of ozanim …
269 results